Sanofi India FY25 ESG Report: Net Zero by 2045 and Emission Cuts

Sanofi India has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ending December 31, 2025. The report outlines the company's environmental, social, and governance (ESG) commitments and performance.

The company reported a turnover for CSR applicability of ₹1,837.40 crore in CY 2025, with a Net Worth of ₹749.20 crore.

Key operational metrics for CY 2025 include total Scope 1 and 2 GHG emissions at 523.50 Metric tons of CO₂ equivalent, total waste generated at 339.78 metric tons, and total water withdrawal at 122,649.60 kilolitres.

Why This Matters

As investor focus on ESG factors grows, this report provides important transparency into Sanofi India's sustainability strategy. Targets like Net Zero by 2045 show a long-term commitment to responsible business practices. This disclosure helps stakeholders evaluate the company's alignment with global sustainability trends and its proactive approach to environmental and social responsibility.

The Backstory

Sanofi India operates under its global parent, Sanofi, which has a stated commitment to sustainability and ambitious carbon neutrality goals. Sanofi India has been aligning with these objectives, participating in and reporting on environmental protection and social welfare initiatives annually.

What's Changing

Shareholders can now track Sanofi India's progress against specific ESG targets, including achieving Net Zero by 2045 and the outlined emission reduction goals. The integration of eco-design principles across its product lifecycle, starting with new medicines and vaccines, marks a key operational change. The company is also improving resource efficiency through initiatives like Zero Liquid Discharge (ZLD) projects.

Risks to Watch

While the report highlights progress, risks remain. Unethical practices could harm Sanofi India's reputation and lead to fines. Health and safety incidents may damage trust and impact product demand. The company's operations also expose employees and contractors to occupational health and safety hazards.

Peer Comparison

Sanofi India's peers, including Cipla Ltd, Sun Pharmaceutical Industries Ltd, and Dr. Reddy's Laboratories Ltd, also disclose their ESG performance. These companies similarly report on environmental metrics like GHG emissions, water usage, and waste management, reflecting a sector-wide emphasis on ESG transparency.

What to Track Next

Investors should monitor Sanofi India's continued focus on achieving its stated ESG targets, particularly the Net Zero commitment and emission reduction milestones. The effective implementation and expansion of eco-design principles across a wider product portfolio will be a key indicator. Tracking the company's overall sustainability performance across its value chain, alongside its waste management and resource efficiency, will offer further insights into its long-term strategy.